-
Aurora Kinase A in Retinoblastoma: Study Insights
2026-08-18
A 2024 study links elevated Aurora kinase A (AURKA) expression in retinoblastoma to histopathologic high-risk features and poor chemotherapy response. By combining patient-tissue analysis with genetic and pharmacologic perturbation across cellular, xenograft, and enucleated-tumor models, the work provides a preclinical rationale for testing selective Aurora A inhibition in high-risk disease.
-
Necrostatin-1 for RIP1 Kinase Necroptosis Assays
2026-08-18
Necrostatin-1 is a selective RIP1 kinase inhibitor for resolving TNF-α-driven necroptosis in cell and tissue-injury models. This guide translates its mechanism into practical workflows, pathway controls, ferroptosis-aware assay design, and troubleshooting strategies.
-
Harpagoside Targets EGFR-TKI Resistance in Lung Cancer
2026-08-17
The reference study links acquired gefitinib resistance in EGFR-mutant lung adenocarcinoma cells to stemness-associated and inflammatory gene changes, EMT-like features, and enhanced tumor behavior. It further shows that harpagoside can enhance gefitinib or paclitaxel responses, with the paclitaxel combination engaging apoptosis and ferroptosis through suppression of Nrf2 signaling.
-
Harpagoside Targets Resistance in EGFR-Mutant NSCLC
2026-08-17
This 2025 Journal of Functional Foods study shows that harpagoside can improve gefitinib and paclitaxel responses in EGFR-mutant lung adenocarcinoma models. Its main mechanistic contribution is linking combination treatment to suppression of Nrf2-associated defenses, with concurrent induction of apoptosis and ferroptosis and reduced metastatic behavior.
-
TRIM21, ERK1/2, and Drug Resistance in Pituitary Adenomas
2026-08-16
The reference study identifies TRIM21 as a regulator of ERK1/2 ubiquitination, phosphorylation, proliferation, and dopamine-agonist resistance in pituitary adenomas. Its combination of CRISPR screening, biochemical validation, resistance models, and NanoBiT-based compound screening positions TRIM21 as a mechanistically supported—but still preclinical—therapeutic target.
-
Morin: Podocyte Energy Assay Workflow
2026-08-15
Morin combines pathway-focused podocyte research with practical fluorescence applications, offering a way to study mitochondrial energy imbalance, AMPD activity, and aluminum-ion detection in parallel. This workflow translates recent fructose-injury findings into reproducible cell, biochemical, and optimization strategies.
-
S63845 MCL1 Inhibitor: Assay Design Guide
2026-08-14
A scenario-based guide to using S63845 MCL1 inhibitor (SKU A8737) in viability, proliferation, and mitochondrial apoptosis assays. It covers mechanism, controls, dosing, solvent handling, interpretation, and practical criteria for selecting a dependable research reagent.
-
USP7–PKM2 Axis in Severe Acute Pancreatitis
2026-08-14
A 2025 Cell Death and Disease study identifies USP7 as an upstream regulator of PKM2-dependent metabolic reprogramming in macrophages during severe acute pancreatitis. Genetic and pharmacological experiments link USP7-mediated PKM2 deubiquitination to M1 polarization, inflammatory injury, and a potentially actionable immunometabolic pathway.
-
Estradiol Workflows for ER Signaling and Autophagy
2026-08-13
Build receptor-aware cell assays, autophagy readouts, and multi-organ validation workflows around 17 beta-estradiol. This guide translates recent cohort, network, and mouse evidence into practical dose design, controls, troubleshooting, and translational assay choices.
-
FBXO22 Ligands Expand Targeted Protein Degradation
2026-08-13
This 2025 bioRxiv preprint develops chemical probes that selectively degrade FBXO22 and introduces 2-pyridinecarboxaldehyde as a recruitment ligand for FBXO22-based targeted protein degradation. The findings provide a route beyond commonly used CRBN and VHL recruiters, while identifying structural and mechanistic parameters that influence FBXO22 activity.
-
HMGB1 as an Early Serum Biomarker for Diabetic Nephropathy
2026-08-12
Peng et al. used quantitative serum proteomics, Mfuzz clustering, and weighted gene co-expression network analysis to identify HMGB1 as a promising candidate for monitoring diabetic nephropathy progression. Validation in high-glucose cell and animal models supports biological relevance, but independent clinical validation and standardized assay thresholds remain necessary before diagnostic implementation.
-
Entinostat: From Chromatin Mechanism to Translation
2026-08-12
A translational framework for using Entinostat (MS-275) to connect HDAC1/3 biology, cancer response metrics, assay design, and therapeutic strategy.
-
How Sodium Overload Executes NECSO
2026-08-11
The Nature Communications study identifies mitochondrial energy failure as the mechanistic link between TRPM4-mediated sodium influx and necrosis by sodium overload, or NECSO. Its findings connect mitochondrial Na⁺ accumulation, NCLX-dependent Ca²⁺ loss, impaired oxidative metabolism, ATP depletion, and membrane rupture into a coherent causal pathway.
-
Probenecid as a Translational Mechanism Probe
2026-08-11
Probenecid is more than a broad transporter inhibitor: it is a useful mechanistic probe for connecting drug efflux, pannexin-1 biology, lysosomal injury, and neuroinflammatory responses. This thought-leadership guide shows how to use Probenecid to design stronger multidrug-resistance and cerebral ischemia/reperfusion studies while maintaining the specificity and translational discipline required for preclinical decision-making.
-
KPT-330 Inhibits Osteoclastogenesis in Osteoarthritis
2026-08-10
A 2026 iScience study identifies KPT-330, also known as Selinexor, as an inhibitor of osteoclast-driven subchondral bone remodeling in osteoarthritis. Using a DMM mouse model and RANKL-induced osteoclastogenesis assays, the authors link protection of bone and cartilage to suppression of NF-κB and MAPK signaling.